Destiny Pharma publish in the European Biopharmaceutical Review Journal “Global Rise in AMR Threatens Infection Armageddon”

Wednesday March 23, 2022

Dr Bill Love, Chief Scientific Officer at Destiny Pharma, writes “The rise of antimicrobial resistance (AMR) has necessitated ongoing initiatives to offset the global threat and promote innovation, with financial incentives being key to spurring new antibacterial drug development”.

To read the full article, please click here:-

European Biopharmaceutical Review journal – Global Rise in AMR Threatens Infection Armageddon – Dr Bill Love – 22 March 2022

This article is taken from European Biopharmaceutical Review April 2022, pages 31-33. © Samedan Ltd